Stimulated whole blood cytokine release as a biomarker of immunosuppression in the critically ill: The need for a standardized methodology

Shock

Volumn 45, Issue 5, 2016, Pages 490-494

  Segre, Elisabetta ^a   Fullerton, James N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnostic; endotoxin tolerance; immunoadjuvant; lipopolysaccharide; sepsis; stratified medicine; therapeutics; tumor necrosis factor

Indexed keywords

INDOMETACIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CELL COUNT; CONCENTRATION (PARAMETERS); CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; HEMODILUTION; HUMAN; IMMUNOCOMPETENCE; MALE; MONOCYTE; NORMAL HUMAN; PROTEIN EXPRESSION; STORAGE TEMPERATURE; VENOUS BLOOD; BLOOD; CRITICAL ILLNESS; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; METABOLISM; REPRODUCIBILITY;

ADULT; BIOMARKERS; CRITICAL ILLNESS; CYTOKINES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IN VITRO TECHNIQUES; LIPOPOLYSACCHARIDES; MALE; REPRODUCIBILITY OF RESULTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964225061     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000557     Document Type: Article

References (21)

1. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 306(23): 2594-2605, 2011.
2. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 15(4): R183, 2011.
3. Leentjens J, KoxM, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?. Am J Respir Crit Care Med. 187(12): 1287-1293, 2013.
4. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 3(6): 678-681, 1997.
5. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-Associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 180(7): 640-648, 2009.
6. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32(8): 1175-1183, 2006.
7. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P, Monneret G. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 36(11): 1859-1866, 2010.
8. Appoloni O, Vincent JL, Duchateau J. Response of tumour necrosis factor-Alpha to delayed in vitro monocyte stimulation in patients with septic shock is related to outcome. Clin Sci (Lond) 102(3): 315-320, 2002.
9. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, Redl H, Roth E, Spittler A. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 25(2): 129-134, 2006.
10. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37(3): 525-532, 2011.
11. Demaret J, Walencik A, Jacob MC, Timsit JF, Venet F, Lepape A, Monneret G. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry B Clin Cytom. 84(1): 59-62, 2013.
12. Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, HoedemaekersCW, Pickkers P. Differential ex vivo and invivo endotoxin tolerance kinetics following human endotoxemia. Crit Care Med. 39(8): 1866-1870, 2011.
13. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med. 29(4): 646-651, 2003.
14. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 85(5): 1341-1347, 1995.
15. Wang JE, Solberg R, Okkenhaug C, Jorgensen PF, Krohn CD, Aasen AO. Cytokine modulation in experimental endotoxemia: characterization of an ex vivo whole blood model. Eur Surg Res. 32(2): 65-73, 2000.
16. Ogata M, Okamoto K, Kohriyama K, Kawasaki T, Itoh H, Shigematsu A. Role of interleukin-10 on hyporesponsiveness of endotoxin during surgery. Crit Care Med. 28(9): 3166-3170, 2000.
17. HeagyW, Nieman K, Hansen C, CohenM, Danielson D, WestMA: Lower levels ofwhole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg Infect (Larchmt) 4(2): 171-180, 2003.
18. Allen ML, Hoschtitzky JA, Peters MJ, Elliott M, Goldman A, James I, Klein NJ. Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit Care Med. 34(10): 2658-2665, 2006.
19. Woiciechowsky C, Asadullah K, Nestler D, Schoning B, Glockner F, Docke WD, Volk HD. Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol. 84(2): 164-171, 1998.
20. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 20(4): 224-233, 2014.
21. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 81(4): 426-439, 2015.